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Abstract This study compares three diVerent hyaluronate
formulations and evaluates functionality, time of satisfac-
tory pain relief and also the delay in performing a total hip
arthroplasty. One hundred and twenty patients (126 hips)
received viscosupplementation with one of the three
hyaluronate formulations. All patients were candidate for
surgical treatment with a total hip arthroplasty. Three diVer-
ent products were consecutively used: Adant®, Synocrom®
or Synvisc®. Patients were assessed 6 weeks after each
inWltration using Visual Analogue Scale and Harris Hip
Score. The Harris Hip Score increased signiWcantly in two
of the three groups compared to baseline, but no statistical
signiWcant diVerence was noted between the groups. Visco-
supplementation provides signiWcant pain reduction in two
of the three groups. There is no signiWcant diVerence in
duration of the eVect of the Wrst inWltration between the
three groups. The positive eVect was still ongoing at the
end point of the study in 46 hips: 51% of the patients did
not undergo total hip arthroplasty, 3 years after viscosup-
plementation.
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Abbreviations
OA Osteo-arthritis
NSAID Non steroidal anti-inXammatory drug
VS Viscosupplementation
HA Hyaluronic acid
THA Total hip arthroplasty
HHS Harris hip score
VAS Visual analogue scale
MW Molecular weight
Introduction
Severe osteoarthritis (OA) of the hip is characterized by
pain and reduced mobility. It aVects primarily adults aged
over 50 years, but the age of onset of hip OA linked
complaints seems to decrease over the last decennia [12].
First-line treatment consists of pain reduction with analge-
sics and non steroidal anti inXammatory drugs (NSAID).
Rehabilitation treatment, education and the use of walking
aids can help providing pain relief and improving mobility.
When those therapeutic options fail or the analgesic
treatment causes intolerable side eVects, joint lavage, hip
osteotomy or total hip arthroplasty (THA) can be consid-
ered. This arthroplasty technique has greatly improved and
patients experience pain reduction and improvement of the
quality of life. However, the intervention still requires
prolonged anaesthesia, and is followed by a long-term reha-
bilitation program. Though complications are rare and
protheses have an increasing duration of life, reinterven-
tions are still needed [4].
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Viscosupplementation (VS) is the administration of
hyaluronan and/or hyaluronic acid preparations to joint
synovial Xuid for the treatment of OA in order to restore the
biologic properties of normal hyaluronic acid (HA).
The use of VS with HA was Wrst described to provide
pain relief and to increase mobility of the knee joint. The
VS is an eVective treatment for OA of the knee with beneW-
cial eVects on pain, function and patient global assessment
[14]. HA products have more prolonged eVects than intra-
articular corticosteroids [14]. Since 1984, this technique is
also used for the management of OA of the hip joint [2]. In
the available literature there is no consensus on the number
of injections, the dosage per injection, the most appropriate
formulation of HA, and the optimal method for controlling
the needle positioning in the hip joint. Moreover, the
patient selection criteria diVer from one study to another.
To our knowledge there is no documentation available on
the possible time gain for patients treated with VS of the
hip joint before they have to undergo THA.
The results of a trial comparing three formulations of
HA were presented. All patients were candidates for THA.
The time of satisfactory pain relief, improved functionality
obtained with each inWltration of HA and the delay in sur-
gery were evaluated.
Patients and methods
Patient selection
The use of VS in patients with severe OA is common prac-
tise in our hospital, thus not requiring approval of the ethi-
cal committee. Patients gave their informed consent for this
prospective study. Between March 2001 and February
2005, 120 patients (126 hips), 49 males and 71 females,
responding to the eligibility criteria listed below, received
viscosupplementation. Three diVerent products were con-
secutively used: Adant® (Tedec-Meiji Failma, Madrid,
Spain) (Group 1) (Synthetic hyaluronic acid with an aver-
age molecular weight of 0.6–1.2 million Da), Synocrom®
(Croma Pharma, Leobendorf, Austria) (Group 2) (Sodium
hyaluronate with a average molecular weight of 1.6 million
Da) or Synvisc® (Altana Pharma, Konstanz, Germany)
(Group 3) (Hylan GF 20 with an average molecular weight
of 6.0 million Da) (Table 1).
Eligibility criteria
• Age between 30 and 70 years and suVering idiopathic
radiologically conWrmed hip OA.
• Visual Analogue Scale (VAS) score for pain greater then
30 (on a 100-point scale; 0 no pain and 100 “the worst
pain imaginable”)
• Have persistent pain for longer than 1 month despite use
of analgesics or NSAID’s.
• Be candidate for surgical treatment with a THA, accord-
ing to the following criteria:
• continuous hip pain, also during the night, requiring
daily intake of NSAID’s or pain medication
• disabled gait pattern and need of walking aid
• Be able to understand the information relative to visco-
supplementation and to give informed consent.
Exclusion criteria
• Pregnancy
• Contraindications to intra-articular hyaluronic-acid prep-
arations
• Major hip dysplasia or congenital abnormality of the hip
• Patients with systemic corticosteroids or intra-articular
corticosteroid injections in the last 6 months
• Contra-lateral THA or hip arthroscopy in the last
6m o n t h s
• Oral or parenteral anticoagulant therapy
• Previous hyaluronic acid hip inWltrations
• Skin diseases or infections
• Signs of haemarthrosis
• History of allergy or hypersensitivity to iodated contrast
Treatment
Patients received an intra articular inWltration with one of
the three products. The manufacturer’s treatment recom-
mendations were followed. Patients having initially experi-
enced a satisfactory pain relief are oVered a second and
third inWltration or THA when the condition deteriorates.
Injection of the viscosupplementation was performed under
sterile conditions by the same experienced orthopaedic sur-
geon (MM) in all patients. After skin cleaning a lumbar
puncture needle was inserted in a lateral approach. Layer by
Table 1 Characteristics of 
inWltrated population
Period of treatment Patients Gender Age
Adant 27-11-02 till 23-02-05 91 35 # and 65 $ 61.8 § 12.8
Synocrom 19-01-04 till 04-10-04 20 7 # and 13 $ 62.1 § 14.5
Synvisc 15-03-01 till 24-04-03 15 7 # and 8 $ 61.9 § 15.3Arch Orthop Trauma Surg (2008) 128:275–280 277
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layer local anaesthesia was performed using lidocaine 1%.
Iodinated contrast agent Ultravist® (Schering, Berlin, Ger-
many) was injected. The needle positioning into the joint
cavity was Xuoroscopically controlled (Fig. 1). Arthrocen-
tesis was carefully performed prior to each injection to
remove any eVusion.
After resting for 2 h, the patient was allowed to walk and
to return home. The patient was advised to rest at home
until the next morning.
Oral symptomatic slow acting drugs for osteoarthritis
were authorized if they were taken at a stable dose for more
than 3 months prior to inclusion in the study. These analge-
sics were continued at a stable dose during the VS treat-
ment.
Evaluation
All patients were assessed at baseline and 6 weeks after
each inWltration. During this consultation in the outpatient
clinic, the pain and functionality were evaluated using the
VAS pain during walking score (100-point scale) and the
Harris Hip Score (HHS). The latter is a clinical scoring sys-
tem on a total of 100 points whereby the following sub-
scales are rated: function (47 points), pain (44 points),
range of motion of the hip (5 points) and absence of muscle
contractures and length discrepancy (4 points). All side
eVects and complications of viscosupplementation were
noted. In April 2005, all patients were contacted for follow-
up assessment over the phone VAS and HHS.
Statistical analysis
Software (MS Excel)® was used to collect the data. Statisti-
cal analyses were of two kinds, Wrst the diVerences in HHS
and VAS pre-inWltration and post-inWltration (in the three
groups) were compared using the paired t test and with the
Wilcoxon paired test in the Synvisc group because this
group is too small to analyse with the paired t test.
The second comparison was made between the three
groups (Synvisc, Synocrom and Adant). The diVerences in
HHS and VAS evolution between the three groups were
checked by the analysis of variance statistics with Tukey
extension, which also was used for controlling if the groups
were initially homogeneous.
The duration of the viscosupplementation eVect of the
Wrst inWltration was analysed using the Kaplan-Meier sur-
vival curves. The delay for the need of hip surgery was also
analysed using a Kaplan-Meier survival curve. The statisti-
cal signiWcance was set on P · 0.05.
Results
The mean pre-inWltration HHS was comparable for the
three groups and varied from 64.8 points in the Adant
group to 66.8 points in the Synocrom-group. The post-inWl-
tration HHS increased with 6.3 points in the Adant group
(P < 0.001), with 10.6 points in the Synocrom group
(P < 0.05) and with 6.1 points in the Synvisc-group
(P >0 . 0 5 ;  T a b l e2). There was no statistical signiWcant
diVerence in the evolution of the HHS between the three
groups (Table 2).
Viscosupplementation provided a highly signiWcant pain
reduction in the Adant-group (P < 0.0001), a signiWcant
pain reduction in the Synocrom-group (P < 0.05) and a pain
reduction that did not reach signiWcance in the Synvisc-
group (P > 0.05). There was no signiWcant diVerence in
pain relief between the three treatment products (Fig. 2,
Table 3).
Fig. 1 a Needle placement for injection of the viscosupplementation.
b Fluoroscopic image of the needle insertion in the hip joint space
Table 2 Evolution in average HHS score
HHS pre HHS post DiVerence P
Adant 64.8 § 13.8 71.1 § 15.7 + 6.3 < 0.001
Synocrom 66.8 § 13.8 77.4 § 14.7 + 10.6 < 0.05
Synvisc 66.3 § 13.5 72.4 § 14.5 + 6.1 > 0.05278 Arch Orthop Trauma Surg (2008) 128:275–280
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The duration of the eVect of the Wrst inWltration in the
three groups is shown in a Kaplan-Meier curve (Fig. 3).
The Wrst inWltration was the starting point. Endpoints were
the second inWltration or operation of the aZicted hip, or
when these were not applicable the latest patient contact,
which can be considered as ongoing eVect.
There is no signiWcant diVerence between the three
groups (2= 0.988 and P = 0.61). Figure 4 illustrates the
duration of eVect of the three groups globally.
The positive eVect was still ongoing in 46 hips, while in
80 hips patients had either received a second inWltration or
THA at, the end of the study (Table 4).
The delay in performing a hip operation is analysed
using a Kaplan-Meier survival curve (Fig. 4). After 3 years,
51% of the patients have not undergone surgery. Because
of the comparable outcome achieved with the three HA for-
mulations, we did not diVerentiate between the three prod-
ucts in this survival analysis (Fig. 5).
Discussion
The patients attending our outpatient clinic, who were
judged eligible for THA, were oVered the possibility of a
VS therapy. Hundred twenty patients choose this treatment
option and 126 hips were treated with Adant, Synocrom or
Synvisc. All studies, published up till now, studying the
eVect of VS in the treatment of hip OA were performed in
small patient groups (12–57 patients) [6, 9].
The three preparations provided a signiWcant pain relief
and improvement of the HHS. The isolated Synvisc group
never reached statistical signiWcance in HHS score evolu-
tion and VAS during walk test after VS treatment; possibly
due to the small number of patients (N = 15) in this group.
As in the study of Tikiz [13], we found no signiWcant diVer-
ence between lower and higher molecular weight hyal-
uronic acids.
We could identify two groups of responders, the ongoing
responders who last on average for 352 days after the Wrst
inWltration. The second group, where patients either
received a second inWltration or THA had an average dura-
tion of eVect of 174 days.
The VS method is widely used for OA of the knee joint,
but there are only a few studies about its use in OA of the
hip. Most authors agree that there should be a role for
viscosupplementation in the treatment of hip OA. [1–3, 6,
7, 9–11] Our Wndings conWrm the eVect of VS in patients
suVering OA of the hip. To our knowledge, this is the larg-
est series of patients with hip osteoarthritis treated with
viscosupplementation. There are no guidelines regarding
Fig. 2 Pain relief in the three treatment groups a Adant, b Synocrom
and c Synvisc
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the optimal number of injections needed to obtain optimal
clinical response, which seems to be diVerent [1, 2, 8, 10,
11] between products and dependent on the molecular
weight (MW) [7]. We evaluated the time to relapse of one
inWltration.
Other authors advocated the use of ultrasound for con-
trolling the needle position in the hip joint. [9, 3] In our
series, we performed the inWltrations under Xuoroscopy, in
experienced hands this approach has proven to be accurate
and safe. We use a very low amount of contrast liquid to
avoid dilution of the product.
Of all the reports published, we have the longest follow-
up, up to approximately 3 years. The analysis by means of
the Kaplan-Meier survival curve learns that there is a 50%
probability of long-term eVect (more than 2 years).
We saw no infectious adverse events and no serious sys-
temic reactions, but all the interventions are performed in
the operating theatre under strict aseptic conditions. The
adverse events rates ranged from 10 to 30% which is
slightly higher than the rates reported in VS treatment of
knee OA [7]. Repeated injections did not increase the risk
of adverse events [7]. Some patients experienced transient
hip pain after the inWltration but made a full recovery in the
next days. In the study of Conrozier [6], transient hip pain
was reported after 10.1% of the injections. The products
used in this study were all well tolerated. Complications are
rare but a single case of septic arthritis was reported after
multiple injections of hyaluronate and glucocorticoid [5].
Gout, pseudogout and chondrocalcinosis have not been
reported after hip inWltrations.
Intra articular injection of hyaluronic acid can provide
long-term pain relief and improvement of joint function
even in patients eligible for THA. Despite the use of Xuo-
roscopy, this technique can be performed in an outpatient
clinic, allowing patients to return home on the day of the
intervention. At present, viscosupplementation therapy for
OA of the hip is only palliative. It can be an alternative for
young THA candidates, patients with surgical contra-indi-
cations and patients in whom NSAID use is not appropri-
ate. There is only 1 randomised, double blind, placebo
controlled trial of patients with hip OA [15]. The study was
designed with a three-armed parallel-group (Hyalgan vs.
methylprednisolone vs. lidocaine). One hundred and one
were treated. There was no statistically signiWcant diVer-
ence between the three products on any outcome measure
including the primary outcome measure, i.e., ‘Pain on
walking’, at three 3 months of follow-up.
The results of our study should be considered in the light
of the limitations of the design of this study. It is a non pla-
cebo controlled non randomised prospective study. It is
known from experience with knee OA that the placebo
eVect of VS tends to be substantial [8]. The dimension of
the groups treated with the three diVerent products diVers
from 15 to 91 patients.
Viscosupplementation with hyaluronic acid seems to be
a valuable technique for the management of painful OA of
Table 3 Evolution in average VAS pain during walking score
Pre: at Wrst inWltration
Post: at follow-up
VAS pre VAS post DiVerence  P
Adant 51 § 23 39 § 27 ¡ 12 < 0.0001
Synocrom 43 § 22 29 § 23 ¡ 14 < 0.02
Synvisc 47 § 26 30 § 29 ¡ 17 > 0.05
Fig. 4 Kaplan-Meier survival 
curve of the duration of eVect of 
the Wrst inWltration in days (three 
treatment groups together)280 Arch Orthop Trauma Surg (2008) 128:275–280
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the hip that may delay the need for surgical intervention.
Further prospective randomised placebo controlled studies
are necessary to draw deWnite conclusions.
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